Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancer: An economic analysis based on prognostic and predictive validation studies

Lyman, Gary H., Cosler, Leon E., Kuderer, Nicole M., Hornberger, John · 2007 · Cancer

Abstract

BACKGROUND: The prognostic accuracy for distant recurrence‐free survival using a 21‐gene reverse‐transcriptase polymerase chain reaction (RT‐PCR) assay underwent validation in 668 lymph node‐negative, estrogen receptor‐positive women with early‐stage breast cancer receiving tamoxifen on National Surgical Adjuvant Breast Program (NSABP) B‐14. The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B‐20 and 645 patients on NSABP B‐14. METHODS: Patients were classified as high (recurrence score [RS] ≥ 31), intermediate (RS 18–30), or low (RS < 18) risk for distant recurrence at 10 years. Cost‐effectiveness ratios were estimated for RS‐guided treatment compared with either tamoxifen alone or the combined chemotherapy and tamoxifen. RESULTS: Distant recurrence was reported in RS low‐risk, intermediate‐risk, and high‐risk patients at 10 years in 3.7%, 17.8%, and 38.3% receiving tamoxifen alone and 5.0%, 10.1%, and 11.1% receiving the chemotherapy and tamoxifen. RS‐guided therapy is associated with a gain in individual life expectancy of 2.2 years compared with tamoxifen alone, whereas it is associated with similar life expectancy to that seen with the chemotherapy and tamoxifen strategy. RS‐guided therapy is estimated to provide a net cost savings of $2256 compared with chemotherapy and tamoxifen with an incremental cost‐effectiveness ratio of $1944 per life year saved compared with tamoxifen alone. CONCLUSIONS: Treatment decisions based on RS‐guided therapy compared with tamoxifen alone are associated with greater efficacy with acceptable cost‐effectiveness ratios, and associated with similar efficacy and lower cost compared with chemotherapy and tamoxifen for patients with lymph node‐negative, estrogen receptor‐positive early‐stage breast cancer. Cancer 2007 © 2007 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.22506

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Lyman, G. H., Cosler, L. E., Kuderer, N. M., & Hornberger, J.
Venue
Cancer
Publisher
Wiley
Published
2007-02-20
Volume
109
Issue
6
Pages
1011-1018
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1991459743
Cited by
179
References
3
FWCI
4.93
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.